An innovator in Cell and Gene Therapy with a proprietary, flexible manufacturing platform that can enable widespread access to lifesaving treatments. Manufacturing Brighter Futures in Cell and Gene Therapy.
Location: United States, New Jersey, East Greenwich Township
Total raised: $139.4M
Founded date: 2015
Founders name: Chris Mason
Founders Related Locations: United Kingdom, England, London; United States, District of Columbia, Washington; United States, Massachusetts, Cambridge; United States, Pennsylvania, Pittsburgh
Investors 3
| Date | Name | Website |
| 09.11.2020 | Octopus Ve... | octopusven... |
| - | Amadeus Ca... | amadeuscap... |
| 02.03.2021 | Delin Vent... | delinventu... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 19.01.2022 | Series B | $100M | - |
| 15.10.2020 | Series A | $30M | - |
| 09.01.2020 | Seed | $9.4M | - |
Persons 1
| Date | First Name | Last Name | Title | |||
| - | Chris | Mason | Founder &a... | linkedin.c... | - | - |
Mentions in press and media 24
| Date | Title | Description |
| 25.10.2024 | Innovations in Drug Delivery: A Leap Towards the Future | In the ever-evolving landscape of healthcare, innovation is the lifeblood that keeps the industry vibrant. Recently, two significant events showcased groundbreaking advancements in drug delivery and biopharmaceuticals. The PDA Universe of P... |
| 24.10.2024 | Global Biopharma Thought Leaders Gather in London: Join the 2024 GenScript Biotech Global Forum for Cutting-Edge Insights | PISCATAWAY, N.J., Oct. 24, 2024 /PRNewswire/ -- Cell therapy, gene therapy, and mRNA vaccines are revolutionizing healthcare, offering innovative treatments for a wide range of diseases. However, as these therapies progress, they encounter ... |
| 15.09.2024 | Dialogue with CGT Leaders! You Are Invited to Join the "2024 GenScript Biotech Global Forum•London" to Discuss the Future Together | PISCATAWAY, N.J., Sept. 15, 2024 /PRNewswire/ -- The year 2024 marks a milestone year for continuous advancements in Cell and Gene Therapy (CGT). The global launch of Amtagvi, a Tumor-Infiltrating Lymphocyte (TIL) therapy, has ushered in a ... |
| 07.12.2023 | Cell and Gene Therapy Manufacturing Industry is projected to surpass a valuation of US$ 240 Billion by 2033 | FMI | FMI Logo USA dominated cell & gene therapy market revenues, driven by active trials & extensive R&D, making North America a leader in trials. NEWARK, DELAWARE, UNITED STATES OF AMERICA, December 7, 2023 /EINPresswire.com/ -- The... |
| 09.11.2023 | Cell and Gene Therapy Manufacturing Market to Achieve a Valuation of USD 8.8 billion by 2031| Analysis by Transparency Market Research | - |
| 06.06.2023 | The Cell and Gene Therapy Manufacturing Market is set to Reach a Valuation of US$ 240 Billion by 2033 end, growing at a CAGR of 29% | Future Market Insights, Inc. | - |
| 02.09.2022 | Jay Bradner’s NIBR exit sets off a succession plan at Merck; Dyne and MorphoSys fill major R&D roles | Jay Bradner → In the Big Pharma world, companies like J&J and Merck have experienced a pronounced sea change in leadership over a two-year period, and you can begin to say the same at Novartis, which dismissed head of d... |
| 19.01.2022 | Ori Biotech raises over $100 million in Series B funding to launch innovative cell and gene therapy manufacturing platform | Ori Biotech raises over $100 million in Series B funding to launch innovative cell and gene therapy manufacturing platform 19-01-2022 Funds will allow for a rapid transition through pre-commercialization to market launch. London, UK and Woo... |
| 19.01.2022 | Ori Biotech raises over $100 million in Series B funding to launch innovative cell and gene therapy manufacturing platform | Funds will allow for a rapid transition through pre-commercialization to market launch. London, UK and Woodcliff Lake, NJ – Ori Biotech Ltd. (Ori), a leader in cell and gene therapy (CGT) manufacturing technology, today announces it has sec... |
| 18.01.2022 | Ori Biotech Raises Over USD100M in Series B Funding | Ori Biotech Ltd., a London, UK- and and New Jersey-based leader in cell and gene therapy (CGT) manufacturing technology, secured over USD 100m in Series B funding. The round was led by Novalis LifeSciences with participation from Puhua Capi... |
Show more